Tagged with Algeria

MENA With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the second largest pharma market on the African continent. Recent reforms have also sped up drug approvals and are turning the…

Morocco Dr Anthony Y. Lauw, GM & Head of Human Pharma Northwest Africa at Boehringer Ingelheim, explains the operations of a cluster that has typically worked with local partners, but that now has also opened a new scientific office in Casablanca with the idea of expanding the company’s on-ground operations in…

Middle East & Africa Apart from a maturing regulatory environment and the expansion of healthcare coverage across the region, a number of other factors are contributing to the evolution of the MEA pharma market. Results from the second wave of a PhRMA-commisioned IQVIA market access study covering Saudi Arabia (KSA), UAE, Kuwait, Lebanon, Jordan,…

Algeria A snapshot of Algeria, one of the key countries driving growth in MENA, a region that accounts for just 2 percent of world’s pharma market but that is estimated to reach around USD 60 billion by 2025. Algeria has steadily improved its essential health care services. Hecho conVisme Infographic Maker…

Roundup A roundup of the latest news from pharma in the Middle East and Africa including China’s announcement that it will be prioritising Africa for access to its COVID-19 vaccine, UAE firm Mubadala’s latest US investment, Saudi Arabia’s continuing digitalisation push, and Algeria’s plan to export USD five billion in domestically…

Opinion In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular PharmaBoardroom contributor Yacine Sellam argues for the need for a more robust regulatory framework in Algeria and even the creation of a unified FDA-style regulator to counter this threat…

Algeria Below we present recent news from Algeria’s pharmaceutical industry, including the creation of a dedicated Ministry to boost the sector, changes to the advertising rules for dietary supplements, and local medical device manufacturers’ efforts in the fight against COVID-19.   Government: Broad prerogatives for the newly created Ministry of Pharmaceutical…

Algeria Drugs, biologicals and medical devices authorization fees are fixed as part of Finance Law in Algeria. Fees are payable by the person who makes the application or submits variations, in local currency for locally-manufactured products, and in convertible foreign currencies for imported ones.   The supplementary Finance Law for 2020…

Algeria In Algeria, the supplementary Finance Law for 2020 has just been published in the Official Gazette. This law materializes the authorities’ will to significantly ease the control of foreign investments in order to boost Foreign Direct Investment (FDI) and to accelerate the diversification of the national economy.   Despite several…

Algeria The ongoing reform of pharmaceutical regulations in Algeria has been marked on January 2020 by publication in the Official Gazette of the long-awaited Decree No 19-379 dated of 31st December 2019. This Decree has laid down procedures for specific administrative, technical and safety control of substances and drugs with psychotropic…

Pharma Legal Handbook A brief overview of the situation regarding biosimilars and biologics. Prepared in association with SAARPE Association, a leading law firm in Algeria, this is an extract from The Pharma Legal Handbook: Algeria, available to purchase here for USD 99.   1. Are biosimilar medicines considered the same as generic medicines…

Pharma Legal Handbook The ins and outs of localization in Algeria. Prepared in association with SAARPE Association, a leading law firm in Algeria, this is an extract from The Pharma Legal Handbook: Algeria, available to purchase here for USD 99.   1. Are there any rules or regulations requiring and/or encouraging localization in…